2A Pharma secures SEK 20 million of funding

2A Pharma is very pleased to announce that it has raised SEK 20 million (USD 2.2M)  from existing and new investors. This funding augments the previously raised SEK 27 million (USD 3M) and will enable 2A Pharma to drive its leading vaccine candidate, 2AP01, a broad coverage prophylactic HPV vaccine formulated without adjuvants, through phase 1 clinical studies and support progress of the pipeline.

S.A.B. Corporate Finance advised 2A Pharma.